APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference

Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference

WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Bank of America Securities Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. PT.

The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for approximately 90 days following the event.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit  or follow us on  and .

Investor Contact: 

Meredith Kaya 

617.599.8178



EN
06/05/2024

Underlying

APLSApellis Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

 PRESS RELEASE
Free
APLS Apellis Pharmac...

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Tra...

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were clearedHighlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress WALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced positive one-year resul...

May 24, 2024 1 EN
Laura Chico
  • Laura Chico
APLS APELLIS PHARMACEUTICALS
05/15/24 May 15, 2024 1 EN
 PRESS RELEASE
Free
APLS Apellis Pharmac...

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Milli...

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Significantly improves liquidity profile by eliminating $366 million in SFJ payments through 2027 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), today announced that it has entered into a non-dilutive, senior secured credit facility with Sixth Street, a...

May 14, 2024 1 EN
 PRESS RELEASE
Free
APLS Apellis Pharmac...

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA no later than July 2024On track to report topline Phase 3 data with systemic pegcetacoplan in C3G / IC-MPGN in mid-2024Cash and cash equivalents of $325.9 million as of March 31, 2024; projected revenues and cash expected to be sufficient to fund operations for foreseeable futureMan...

May 7, 2024 1 EN
Laura Chico
  • Laura Chico
APLS APELLIS PHARMACEUTICALS
05/07/24 May 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch